You Position: Home > Paper
Progress of diagnosis and treatment of cytokine release syndrome after CD19 chimeric antigen receptor T cells therapy
( views:69, downloads:18 )
- Author:
- No author available
- Journal Title:
- Journal of Leukemia and Lymphoma
- Issue:
- 9
- DOI:
- 10.3760/cma.j.cn115356-20210109-00009
- Key Word:
- 受体，抗原，T细胞;细胞因子受体gp130;免疫疗法;Receptors, antigen, T-cell;Cytokine receptor gp130;Immunotherapy
Abstract： CD19 chimeric antigen receptor T cells (CAR-T) therapy is a new immunotherapy for B-cell hematological tumors, and has good efficacy. With the increase of its use, the incidence of immune effector cell-associated cytokine release syndrome is increasing, and further clinical research on its precise mechanism and treatment is urgently needed. This review summarizes the mechanisms, clinical manifestations, grading systems, treatments and management strategies of cytokine release syndrome.
- [1]李小秋.弥漫性大B细胞淋巴瘤的分子分型[J].2020,(10).
- [2]Patrizia,Mondello,Saber,Tadros,Matt,Teater,etc.Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.[J].2020,10(3).
- [3]Mesin, Luka,Ersching, Jonatan,Victora, Gabriel D..Germinal Center B Cell Dynamics[J].2016,45(3).
- [4]A A, Alizadeh,M B, Eisen,R E, Davis,etc.Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.[J].2000,403(6769).
- [5]Schmitz, R.,Wright, G. W.,Huang, D. W.,etc.Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma[J].2018,378(15).
- [6]Ennishi, Daisuke,Takata, Katsuyoshi,Beguelin, Wendy,etc.Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition[J].2019,9(4).
- [7]Christine P,Hans.Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.[J].2004,103.
- [8]Crump, Michael,Neelapu, Sattva S.,Farooq, Umar,etc.Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study[J].2017,130(16).
- [9]Neelapu, S. S.,Locke, F. L.,Bartlett, N. L.,etc.Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma[J].2017,377(26).
- [10]Norberg, Erik,Lako, Ana,Chen, Pei-Hsuan,etc.Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets[J].2017,24(2).
- [11]De Silva, Nilushi S.,Klein, Ulf.Dynamics of B cells in germinal centres[J].2015,15(3).
- [12]Wright, George W.,Huang, Wei,Phelan, James D.,etc.A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications[J].2020,37(4).
- [13]Li, Shaoying,Young, Ken H.,Medeiros, L. Jeffrey.Diffuse large B-cell lymphoma[J].2018,50(1).
- [14]Stefano, Monti,Kerry J, Savage,Jeffery L, Kutok,etc.Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.[J].2005,105(5).
- [15]Jais, Jean-Philippe,Molina, Thierry Jo,Ruminy, Philippe,etc.Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay[J].2017,102(10).
- [16]Caro,P.,Kishan,A.,Norberg,E.,etc.Metabolic Signatures Uncover Distinct Targets in Molecular Subsets of Diffuse Large B Cell Lymphoma[J].2012,22(4).
- [17]David W Scott,George W Wright,P Mickey Williams,etc.Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.[J].2014,123(8).
- [18]Chapuy, Bjoern,Stewart, Chip,Dunford, Andrew J.,etc.Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes[J].2018,24(5).
- [19]Vermaat, Joost S.,Pals, Steven T.,Younes, Anas,etc.Precision medicine in diffuse large B-cell lymphoma: hitting the target[J].2015,100(8).